The next chapter in Alzheimer's disease treatment: Antiamyloid monoclonal antibodies.

The article focuses on the potential of antiamyloid monoclonal antibodies (MABs) as a promising treatment for Alzheimer's disease (AD). Topics include the role of amyloid plaques in the development of AD and the evolution of the amyloid hypothesis, advancements in diagnostic tools such as blood tests and retinal hyperspectral imaging, and recent treatment breakthroughs like Aducanumab and Lecanemab, which target amyloid-beta plaques in the brain.